[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.100.232. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 232
Citations 0
Correction
September 2018

Missing Potential Conflict of Interest

JAMA Pediatr. 2018;172(9):891. doi:10.1001/jamapediatrics.2018.2494

In the Letter in Reply titled “Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy,”1 published online on May 7, 2018, no conflicts of interest were disclosed. The Conflict of Interest Disclosures should have been “Dr Prasad reports receiving royalties from his book Ending Medical Reversal; that his work is funded by the Laura and John Arnold Foundation; that he has received honoraria for Grand Rounds/lectures from several universities, medical centers, and professional societies; and that he is not compensated for his work at the Veterans Affairs Medical Center in Portland, Oregon, or the Health Technology Assessment Subcommittee of the Oregon Health Authority.” This article was corrected online.

References
1.
Prasad  V.  Cost-effectiveness of nusinersen for spinal muscular atrophy-reply  [published online May 7, 2018].  JAMA Pediatr. doi:10.1001/jamapediatrics.2018.0733PubMedGoogle Scholar
×